DrugPatentWatch Database Preview

Details for Patent: 10,213,386

« Back to Dashboard

Which drugs does patent 10,213,386 protect, and when does it expire?

Patent 10,213,386 protects IMBRUVICA and is included in one NDA.

This patent has seventeen patent family members in fifteen countries.

Summary for Patent: 10,213,386

Title:	Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Abstract:	Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):	Chong; Ching W. (Fremont, CA), Kuehl; Robert (San Francisco, CA), Tan; Heow (Cupertino, CA), Atluri; Harisha (Palo Alto, CA)
Assignee:	Pharmacyclics LLC (Sunnyvale, CA)
Application Number:	15/970,721
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,213,386
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,213,386

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-001	Feb 16, 2018		RX	Yes	No			Y
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-002	Feb 16, 2018		RX	Yes	No			Y
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	No			Y

International Family Members for US Patent 10,213,386

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	103832
Australia	2016226279
Brazil	112017018931